INVESTIGATION ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm – YIN, BLDR, PTI, CGIX

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating:

Yintech Investment Holdings Limited (NASDAQ: YIN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a group of rollover shareholders that includes members of Yintech’s management and board of directors. Under the terms of the merger agreement, holders of Yintech ordinary shares will receive $0.365 in cash per share, and holders of Yintech American depository shares (“ADS”) will receive $7.30 in cash per ADS. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/yintech-investment-holdings-limited-yin-stock-merger/.

Builders FirstSource, Inc. (NASDAQ: BLDR) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with BMC Stock Holdings, Inc. Under the terms of the agreement, BMC shareholders will receive 1.3125 shares of Builders FirstSource common stock for each share of BMC common stock. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/builders-firstsource-inc-bldr-stock-merger-bmc/.

Proteostasis Therapeutics, Inc. (NASDAQ: PTI) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Yumanity Therapeutics. Under the terms of the merger agreement, Proteostasis will acquire all outstanding shares of Yumanity in exchange for newly-issued shares of Proteostasis common stock, with existing Proteostasis shareholders expected to own approximately 32.5% of the combined company. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/proteostasis-therapeutics-inc-pti-yumanity-stock-merger/.

Cancer Genetics, Inc. (NASDAQ: CGIX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with StemoniX, Inc. Under the merger agreement, Cancer Genetics will acquire all of the outstanding capital stock of StemoniX in exchange for a number of shares of its common stock, with current equity holders of Cancer Genetics expected to own 22% of the common stock of the combined company. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/cancer-genetics-inc-cgix-stock-merger-stemonix/.

Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at [phone] or email [e-mail] or [e-mail].

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.